Zymeworks Inc. (ZYME) shareholders
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30121% above fair value
$26.47−2.60 (-8.94%)
Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
98.1%
70M of 71M shares
Institutional holders
203
25 new, 29 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 11 sales
Net sold $5.03M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (30.70%), EcoR1 Capital Fund Qualified, L.P. (28.80%) | 22,970,388 | 30.70% | 13D (active) amendment | Nov 16, 2025 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (25.40%), EcoR1 Capital Fund Qualified, L.P. (23.90%) | 17,699,774 | 25.40% | 13D (active) amendment | Apr 4, 2025 |
| David Rosen Joint filing with Rubric Capital Management LP (9.49%) | 7,000,000 | 9.49% | 13G (passive) amendment | Mar 31, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (5.60%) | 4,150,627 | 5.60% | 13G (passive) amendment | Jun 30, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.40%), Perceptive Life Sciences Master Fund, Ltd. (5.40%) | 3,974,579 | 5.40% | 13G (passive) | Apr 8, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (5.20%), Bvf Inc/Il (5.20%) | 3,938,641 | 5.20% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZYME | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | 32.37% | $600.45M | – | 29.19% |
| Rubric Capital Management LP | 7,000,000 | 9.86% | $182.98M | – | 1.68% |
| BlackRock, Inc. | 4,251,030 | 5.99% | $111.12M | −302,858 | 0.00% |
| Perceptive Advisors LLC | 4,182,953 | 5.89% | $109.34M | +672,875 | 1.64% |
| Bvf Inc/Il | 3,649,142 | 5.14% | $95.39M | −85,000 | 2.44% |
| Assenagon Asset Management S.A. | 2,504,054 | 3.53% | $65.46M | +1,776,068 | 0.04% |
| Morgan Stanley | 2,231,260 | 3.14% | $58.33M | −249,308 | 0.00% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | 2.51% | $46.56M | −126,923 | 0.05% |
| Vanguard Capital Management LLC | 1,558,998 | 2.20% | $40.75M | −146,582 | 0.00% |
| Nextech Invest, Ltd. | 1,113,946 | 1.57% | $29.12M | – | 1.38% |
| State Street Corp | 1,088,216 | 1.53% | $28.45M | +76,439 | 0.00% |
| Dimensional Fund Advisors LP | 994,955 | 1.40% | $26.00M | −144,180 | 0.00% |
| Citadel Advisors LLC | 914,136 | 1.29% | $23.90M | −235,882 | 0.00% |
| Nomura Asset Management International Inc. | 889,802 | 1.25% | $23.26M | New | 0.03% |
| FMR LLC | 702,568 | 0.99% | $18.37M | +35,415 | 0.00% |
| Geode Capital Management, LLC | 692,410 | 0.98% | $18.10M | +32,470 | 0.00% |
| Prosight Management, LP | 674,434 | 0.95% | $17.63M | +135,385 | 3.04% |
| Qube Research & Technologies Ltd | 593,590 | 0.84% | $15.52M | +81,653 | 0.01% |
| Vanguard Portfolio Management LLC | 510,032 | 0.72% | $13.33M | +10,157 | 0.00% |
| Redmile Group, LLC | 491,654 | 0.69% | $12.85M | – | 0.86% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 203 | 70M | 98.1% | 25 / 61 | 73 / 29 | 5M | 6M |
| Q1 2026 | 212 | 70M | 99.1% | 40 / 77 | 58 / 35 | 9M | 7M |
| Q4 2025 | 209 | 71M | 100.0% | 47 / 70 | 63 / 19 | 12M | 14M |
| Q3 2025 | 183 | 74M | 100.0% | 25 / 61 | 65 / 23 | 6M | 8M |
| Q2 2025 | 181 | 76M | 100.0% | 29 / 62 | 55 / 30 | 12M | 7M |
| Q1 2025 | 184 | 71M | 99.5% | 32 / 60 | 64 / 17 | 11M | 5M |
| Q4 2024 | 172 | 66M | 93.7% | 31 / 47 | 61 / 20 | 5M | 6M |
| Q3 2024 | 163 | 67M | 93.9% | 26 / 43 | 52 / 25 | 9M | 7M |
| Q2 2024 | 164 | 68M | 96.2% | 24 / 58 | 55 / 28 | 9M | 17M |
| Q1 2024 | 171 | 78M | 100.0% | 32 / 66 | 39 / 17 | 11M | 2M |
| Q4 2023 | 157 | 70M | 98.4% | 33 / 55 | 40 / 14 | 10M | 3M |
| Q3 2023 | 139 | 62M | 87.9% | 22 / 50 | 39 / 19 | 4M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
185 funds held ZYME in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ZYME | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,508,613 | 2.13% | $39.44M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,207,865 | 1.70% | $31.57M | 0.04% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 600,846 | 0.85% | $15.71M | 1.34% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 512,747 | 0.72% | $11.25M | 0.03% | Jul 31, 2026 |
| iShares Biotechnology ETF | 500,560 | 0.71% | $13.08M | 0.14% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 434,367 | 0.61% | $11.35M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 369,100 | 0.52% | $8.10M | 0.09% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 256,110 | 0.36% | $6.44M | 0.04% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 218,946 | 0.31% | $5.50M | 0.10% | May 29, 2026 |
| U.S. Small Cap Portfolio | 194,463 | 0.27% | $4.27M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 189,632 | 0.27% | $4.16M | 0.03% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 184,050 | 0.26% | $4.04M | 0.09% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 166,863 | 0.24% | $3.66M | 0.05% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 156,803 | 0.22% | $3.44M | 0.15% | Jul 31, 2026 |
| Nomura VIP Small Cap Growth Series | 117,152 | 0.17% | $3.06M | 1.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO, Director | 226,842 | 0.32% | Jan 12, 2026 |
| Adam Schayowitz | EVP, Head of R&D | 23,205 | 0.03% | Oct 9, 2026 |
| Mark Hollywood | EVP & Chief Operating Officer | 133,852 | 0.19% | Jul 6, 2026 |
| Paul R. Schneider | EVP, General Counsel | 0 | – | May 15, 2026 |
| Scott Platshon | EVP, Chief Business Officer | 0 | – | Apr 10, 2026 |
| Kristin Stafford | EVP, Chief Financial Officer | 0 | – | Apr 7, 2026 |
| Sabeen Mekan | SVP & Chief Medical Officer | 0 | – | Feb 2, 2026 |
| Jeffrey T. L. Smith | EVP & Chief Medical Officer | 26,708 | 0.04% | Jan 12, 2026 |
| Paul Andrew Moore | Chief Scientific Officer | 48,497 | 0.07% | Jan 12, 2026 |
| Leone D. Patterson | EVP, Chief Bus & Fin Officer | 459 | 0.00% | Jan 7, 2026 |
| Brian N. Cherry | Director | 0 | – | Jan 13, 2026 |
| Carlos Campoy | Director | 0 | – | Jan 12, 2026 |
| Gregory Austin Ciongoli | Director | 493,500 | 0.70% | Jan 12, 2026 |
| Alessandra Cesano | Director | 0 | – | Jan 12, 2026 |
| Robert E. Landry | Director | 0 | – | Jan 12, 2026 |
| Susan Mahony | Director | – | – | Jan 12, 2026 |
| Kelvin Neu | Director | – | – | Jan 12, 2026 |
| Oleg Nodelman | Director, 10% owner | 22,970,388 | 32.37% | Jun 27, 2025 |
| EcoR1 Capital, LLC | Director, 10% owner | 17,883,908 | 25.20% | Jun 27, 2025 |
| Derek John Michael Miller | Director | 0 | – | Dec 12, 2024 |
| Nancy Davidson | Director | 0 | – | Dec 12, 2024 |
| Neil Gallagher | Director | 0 | – | Dec 12, 2024 |
| Troy Cox | Director | – | – | Dec 12, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam Schayowitz EVP, Head of R&D | Oct 9, 2026 | Sale | −13,832 | $25.85 | $357.56K | 23,205 |
| Adam Schayowitz EVP, Head of R&D | Oct 9, 2026 | Option exercise | +37,037 | – | – | 37,037 |
| Mark Hollywood EVP & Chief Operating Officer | Jul 6, 2026 | Award | +939 | $22.22 | $20.86K | 133,852 |
| Mark Hollywood EVP & Chief Operating Officer | Jan 12, 2026 | Sale | −6,120 | $22.67 | $138.74K | 132,913 |
| Mark Hollywood EVP & Chief Operating Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 139,033 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 12, 2026 | Sale | −9,310 | $22.67 | $211.06K | 26,708 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 36,018 |
| Kenneth Galbraith Chair & CEO, Director | Jan 12, 2026 | Sale | −30,424 | $22.67 | $689.71K | 226,842 |
| Kenneth Galbraith Chair & CEO, Director | Jan 12, 2026 | Option exercise | +64,000 | – | – | 257,266 |
| Paul Andrew Moore Chief Scientific Officer | Jan 12, 2026 | Sale | −9,560 | $22.67 | $216.73K | 48,497 |
| Paul Andrew Moore Chief Scientific Officer | Jan 12, 2026 | Option exercise | +17,666 | – | – | 58,057 |
| Leone D. Patterson EVP, Chief Bus & Fin Officer | Jan 6, 2026 | Award | +459 | $10.55 | $4.84K | 459 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 5, 2026 | Sale | −10,538 | $25.10 | $264.50K | 18,352 |
| Jeffrey T. L. Smith EVP & Chief Medical Officer | Jan 5, 2026 | Option exercise | +20,000 | – | – | 28,890 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Option exercise | +20,000 | – | – | 51,212 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Option exercise | +17,168 | – | – | 40,501 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Sale | −9,289 | $25.10 | $233.15K | 31,212 |
| Paul Andrew Moore Chief Scientific Officer | Jan 5, 2026 | Sale | −10,821 | $25.10 | $271.61K | 40,391 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Option exercise | +66,666 | – | – | 224,952 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Sale | −22,657 | $25.10 | $568.69K | 158,286 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Sale | −31,686 | $25.10 | $795.32K | 193,266 |
| Kenneth Galbraith Chair & CEO, Director | Jan 5, 2026 | Option exercise | +47,668 | – | – | 180,943 |
| Kenneth Galbraith Chair & CEO, Director | Dec 22, 2025 | Option exercise | +100,000 | – | – | 180,803 |
| Kenneth Galbraith Chair & CEO, Director | Dec 22, 2025 | Sale | −47,528 | $27.02 | $1.28M | 133,275 |
| Gregory Austin Ciongoli Director | Aug 12, 2025 | Award | +415,000 | $12.02 | $4.99M | 488,500 |
| Oleg Nodelman Director, 10% owner | Jun 26, 2025 | Tax withholding | −41 | $12.71 | $521 | 22,970,388 |
| Oleg Nodelman Director, 10% owner | Jun 26, 2025 | Option exercise | +5,086,480 | – | – | 22,970,388 |
| EcoR1 Capital, LLC Director, 10% owner | May 19, 2025 | Buy | +5,919 | $11.78 | $69.73K | 17,883,908 |
| EcoR1 Capital, LLC Director, 10% owner | May 15, 2025 | Buy | +49,502 | $11.43 | $565.81K | 17,877,989 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 17, 2025 | Buy | +54,760 | $11.52 | $630.84K | 17,828,487 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 16, 2025 | Buy | +73,953 | $11.16 | $825.32K | 17,773,727 |
| Oleg Nodelman Director, 10% owner | Apr 4, 2025 | Buy | +196,438 | $11.17 | $2.19M | 17,699,774 |
| Oleg Nodelman Director, 10% owner | Apr 3, 2025 | Buy | +120,770 | $11.84 | $1.43M | 17,503,336 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 2, 2025 | Buy | +74,360 | $11.85 | $881.17K | 17,382,566 |
| EcoR1 Capital, LLC Director, 10% owner | Apr 1, 2025 | Buy | +48,658 | $11.60 | $564.43K | 17,308,206 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 31, 2025 | Buy | +4,397 | $11.75 | $51.66K | 17,259,548 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 26, 2025 | Buy | +43,848 | $12.24 | $536.70K | 17,255,151 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 25, 2025 | Buy | +53,501 | $12.91 | $690.70K | 17,211,303 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 24, 2025 | Buy | +22,689 | $13.08 | $296.77K | 17,157,802 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 21, 2025 | Buy | +31,033 | $12.78 | $396.60K | 17,135,113 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 20, 2025 | Buy | +73,476 | $12.93 | $950.04K | 17,104,080 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 19, 2025 | Buy | +58,306 | $12.64 | $736.99K | 17,030,604 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 18, 2025 | Buy | +113,880 | $12.65 | $1.44M | 16,972,298 |
| EcoR1 Capital, LLC Director, 10% owner | Mar 17, 2025 | Buy | +56,277 | $12.23 | $688.27K | 16,858,418 |
| Oleg Nodelman Director, 10% owner | Mar 13, 2025 | Buy | +468,356 | $12.48 | $5.85M | 16,802,141 |
| Oleg Nodelman Director, 10% owner | Mar 12, 2025 | Buy | +292,934 | $12.25 | $3.59M | 16,333,785 |
| Oleg Nodelman Director, 10% owner | Mar 11, 2025 | Buy | +320,690 | $11.49 | $3.68M | 16,040,851 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 17, 2025 | Buy | +19,748 | $13.87 | $273.90K | 15,720,161 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 16, 2025 | Buy | +121,681 | $13.89 | $1.69M | 15,700,413 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 15, 2025 | Buy | +39,029 | $14.01 | $546.80K | 15,578,732 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 14, 2025 | Buy | +54,500 | $13.56 | $739.02K | 15,539,703 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 13, 2025 | Buy | +74,125 | $13.39 | $992.53K | 15,485,203 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 10, 2025 | Buy | +204,098 | $13.13 | $2.68M | 15,411,078 |
| EcoR1 Capital, LLC Director, 10% owner | Jan 8, 2025 | Buy | +21,021 | $14.07 | $295.77K | 15,206,980 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Option exercise | +47,666 | – | – | 71,428 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Sale | −33,406 | $14.92 | $498.42K | 80,803 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Option exercise | +66,666 | – | – | 114,209 |
| Kenneth Galbraith Chair & CEO, Director | Jan 6, 2025 | Sale | −23,885 | $14.92 | $356.36K | 47,543 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Option exercise | +17,166 | – | – | 24,533 |
| Paul Andrew Moore Chief Scientific Officer | Jan 6, 2025 | Sale | −9,792 | $14.92 | $146.10K | 14,741 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
20.29%
6M shares short
Days to cover
4.3
At 1M shares a day
Change since last report
+6.0%
From 6M shares
Short volume, 20 days
59.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Zymeworks's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,984 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Adam Schayowitz officer | Oct 9, 2026 | 13,832 | $349.40K | Oct 9, 2026 | Vesting of Restricted Stock Units |
| Jeffrey T. L. Smith Former Officer | Mar 6, 2026 | 247,333 | $6.13M | Mar 6, 2026 | Exercise of Options |
| Leone D. Patterson Former officer | Feb 17, 2026 | 31,641 | $715.09K | Feb 17, 2026 | Exercise of options |
| Leone D. Patterson Former officer | Feb 13, 2026 | 128,548 | $2.98M | Feb 13, 2026 | Exercise of options |
| Paul Andrew Moore Officer | Jan 12, 2026 | 9,560 | $221.51K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Mark Hollywood Officer | Jan 12, 2026 | 6,120 | $141.80K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Kenneth Galbraith Officer, Director | Jan 12, 2026 | 30,424 | $704.92K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Leone D. Patterson Former officer | Jan 12, 2026 | 6,832 | $158.30K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Jeffrey T. L. Smith Officer | Jan 12, 2026 | 9,310 | $215.71K | Jan 12, 2026 | Vesting of Restricted Stock Units |
| Jeffrey T. L. Smith Officer | Jan 5, 2026 | 10,538 | $280.52K | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Paul Andrew Moore Officer | Jan 5, 2026 | 20,110 | $535.33K | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Kenneth Galbraith Officer, Director | Jan 5, 2026 | 54,343 | $1.45M | Jan 5, 2026 | Vesting of Restricted Stock Units |
| Kenneth Galbraith Officer, Director | Dec 22, 2025 | 47,528 | $1.29M | Dec 22, 2025 | Vesting of Restricted Stock Units |
| Derek John Michael Miller Former Director | Nov 24, 2025 | 118,000 | $2.81M | Nov 24, 2025 | Exercise of options |
| Neil Gallagher Former Director | Nov 21, 2025 | 105,000 | $2.50M | Nov 21, 2025 | Exercise of options |
See a number that looks wrong?